{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:56:09Z","timestamp":1790384169652,"version":"4.1.0"},"reference-count":26,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,6,25]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Unravelling the performance of disease activity measures in peripheral spondyloarthritis (pSpA) is crucial for the development of clinical studies. We aimed to evaluate the construct validity and discriminatory capacity of various instruments assessing disease activity and response criteria in patients with pSpA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Post-hoc analysis of the CRESPA randomised controlled trial including patients with early active pSpA. Patients were randomised to golimumab (GOL) or placebo (PBO). Data of the placebo-controlled part until week 12 were used. Construct validity (known group discrimination assessed with standardised mean difference, SMD) in the 12-week data, longitudinal construct validity (ie, standardised response mean and effect size) and trial discrimination (SMD) of several disease activity instruments were assessed. As part of trial discrimination, a \u03c7<jats:sup>2<\/jats:sup> test was performed for binary outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 60 patients (40 GOL, 20 PBO) were included. Construct validity was better for composite outcomes (ie, Disease Activity in Psoriatic Arthritis (DAPSA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Axial Spondyloarthritis Disease Activity Score (ASDAS)\u2014higher SMD between active and inactive patients). Longitudinal construct validity was consistently good for composite outcomes (eg, ASDAS, DAPSA) and global assessments (Patient Global Assessment (PGA), Physician Global Assessment (PhGA)). Clinical trial discrimination was good for composites (BASDAI, ASDAS, DAPSA), global assessments (PGA, PhGA) and joint counts (swollen joint count (SJC66) and tender joint count (TJC68)).<\/jats:p>\n                  <jats:p>Among binary outcomes, trial discrimination was strongest for clinical remission (ie, absence of arthritis, enthesitis and dactylitis), BASDAI50, DAPSA-Low Disease Activity (LDA) and ASDAS-LDA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>While both composite and global outcome measurement instruments performed well in pSpA, composite scores like DAPSA, ASDAS and BASDAI showed better construct validity. The clinical remission definition was the most discriminatory response criterion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005525","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:45:20Z","timestamp":1752579920000},"page":"e005525","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-5837","authenticated-orcid":false,"given":"Clementina","family":"L\u00f3pez-Medina","sequence":"first","affiliation":[{"name":"Rheumatology, Reina Sofia University Hospital, Cordoba, Spain"},{"name":"GC05, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain"},{"name":"Medical and Surgical Sciences Department, University of Cordoba, Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-0416","authenticated-orcid":false,"given":"Dafne","family":"Capelusnik","sequence":"additional","affiliation":[{"name":"Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"Department of Rheumatology, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"Webers","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[{"name":"Rheumatology, VIB Center for Inflammation Research, Ghent, Belgium"},{"name":"Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-9533","authenticated-orcid":false,"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-6171","authenticated-orcid":false,"given":"Philippe","family":"Carron","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-1986","authenticated-orcid":false,"given":"Anna","family":"Molto","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Cochin, AP-HP, Paris, France"},{"name":"INSERM U1153, CRESS\u2014Universit\u00e9 Paris-Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Centre, Heerlen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2025090312321508000_11.3.e005525.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.07.021"},{"key":"2025090312321508000_11.3.e005525.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"key":"2025090312321508000_11.3.e005525.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2025090312321508000_11.3.e005525.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202976"},{"key":"2025090312321508000_11.3.e005525.5","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090312321508000_11.3.e005525.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207235"},{"key":"2025090312321508000_11.3.e005525.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2025090312321508000_11.3.e005525.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090312321508000_11.3.e005525.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"2025090312321508000_11.3.e005525.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210075"},{"key":"2025090312321508000_11.3.e005525.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210775"},{"key":"2025090312321508000_11.3.e005525.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2025090312321508000_11.3.e005525.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.127"},{"key":"2025090312321508000_11.3.e005525.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"key":"2025090312321508000_11.3.e005525.15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"2025090312321508000_11.3.e005525.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"2025090312321508000_11.3.e005525.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2025090312321508000_11.3.e005525.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181218"},{"key":"2025090312321508000_11.3.e005525.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k4817","article-title":"When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation","volume":"364","author":"Murad","year":"2019","journal-title":"BMJ"},{"key":"2025090312321508000_11.3.e005525.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.08.011"},{"key":"2025090312321508000_11.3.e005525.21","doi-asserted-by":"crossref","unstructured":"Capelusnik D , Lopez-Medina C , van der Heijde D , et al . Evaluation of instruments assessing peripheral arthritis in spondyloarthritis: an analysis of the ASAS-PerSpA study. Ann Rheum Dis 2025;Ann Rheum Dis. doi:10.1016\/j.ard.2025.02.011","DOI":"10.1016\/j.ard.2025.05.644"},{"key":"2025090312321508000_11.3.e005525.22","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090312321508000_11.3.e005525.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2025090312321508000_11.3.e005525.24","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2025090312321508000_11.3.e005525.25","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90069-5"},{"key":"2025090312321508000_11.3.e005525.26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"Heijde","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:32:26Z","timestamp":1756927946000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,15]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/rmdopen-2025-005525"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005525","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}